biostudies-literatureUnknown82Sandhu GPart 2 of the International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) offers drug-specific consensus recommendations based on both evidence and practical experience. These recommendations build upon the kidney function assessment and classification guidelines established in Part 1 of ADDIKD. Here we illustrate how dosing recommendations differ between ADDIKD and existing guidance for four commonly used drugs: methotrexate, cisplatin, carboplatin and nivolumab. We then describe how the recommendations can be distilled into practice points for methotrexate and cisplatin. While ADDIKD is a significant improvement from previous guidelines, adoption of this new guideline requires further endorsement from key external stakeholders, 'change championing' by cliniEClinicalMedicine103161https://www.ebi.ac.uk/biostudies/studies/S-EPMC12034076biostudies-literatureIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice.PMC12034076Shingleton JMirkov SScuderi CWard RLMalyszko JSprangers BStein BNKurkard CMichael MO'Neill NLucas CKelly AJohnson DWBoddy AVKichenadasse GKliman DSBagnis CMorris EKarapetis CIbrahim KRoberts DMSiderov JAdattini JTey AWong RFlynn ALiauw WPollock CAWebber KMallett AJRoutledge DJShortt JArmstrong Gordon EHamilton BMcCaughan GChambers PKerr KAWichart JSandhu GADDIKD Working GroupfalseIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice.Part 2 of the International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) offers drug-specific consensus recommendations based on both evidence and practical experience. These recommendations build upon the kidney function assessment and classification guidelines established in Part 1 of ADDIKD. Here we illustrate how dosing recommendations differ between ADDIKD and existing guidance for four commonly used drugs: methotrexate, cisplatin, carboplatin and nivolumab. We then describe how the recommendations can be distilled into practice points for methotrexate and cisplatin. While ADDIKD is a significant improvement from previous guidelines, adoption of this new guideline requires further endorsement from key external stakeholders, 'change championing' by clini2025-01-01T00:00:00Z2025 Apr2025-07-08T03:10:51.281Z2025-07-08T03:10:51.281ZS-EPMC120340764029084410.1016/j.eclinm.2025.103161